Shares of ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $36.50.
ABVX has been the topic of several recent analyst reports. Laidlaw assumed coverage on ABIVAX Société Anonyme in a research note on Monday, July 29th. They issued a "buy" rating and a $48.00 price target on the stock. BTIG Research initiated coverage on shares of ABIVAX Société Anonyme in a report on Monday, May 20th. They issued a "buy" rating and a $43.00 price target for the company.
Read Our Latest Stock Analysis on ABIVAX Société Anonyme
ABIVAX Société Anonyme Stock Up 2.5 %
Shares of NASDAQ:ABVX traded up $0.30 during midday trading on Wednesday, reaching $12.26. The company's stock had a trading volume of 70,614 shares, compared to its average volume of 82,757. ABIVAX Société Anonyme has a fifty-two week low of $7.99 and a fifty-two week high of $17.02. The company has a quick ratio of 4.08, a current ratio of 4.08 and a debt-to-equity ratio of 0.23. The firm has a 50 day moving average price of $12.28 and a two-hundred day moving average price of $13.50.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets purchased a new stake in shares of ABIVAX Société Anonyme in the first quarter worth approximately $81,000. Capstone Investment Advisors LLC purchased a new stake in ABIVAX Société Anonyme in the 4th quarter valued at $618,000. Ghisallo Capital Management LLC bought a new position in ABIVAX Société Anonyme during the 4th quarter valued at $642,000. Kennedy Capital Management LLC boosted its holdings in ABIVAX Société Anonyme by 35.3% during the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company's stock worth $1,718,000 after acquiring an additional 31,331 shares during the last quarter. Finally, Rosalind Advisors Inc. bought a new stake in shares of ABIVAX Société Anonyme in the 1st quarter worth $5,411,000. Institutional investors and hedge funds own 47.91% of the company's stock.
About ABIVAX Société Anonyme
(
Get Free ReportABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Read More
Before you consider ABIVAX Société Anonyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.
While ABIVAX Société Anonyme currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
